|
|
13:00-14:00, Auditorium 8 |
|
|
Biotronik AG |
SY 401
|
InteREACTive debate on CLI treatment, a multidisciplinary approach for multilevel disease |
|
|
|
|
|
Debate on CLI treatment options between panel and audience based on pre-recorded challenging cases |
|
|
|
|
|
Moderators: K. Deloose (Dendermonde/BE), J.C. van den Berg (Lugano/CH) |
|
|
|
|
|
Panellists: Y. Gouëffic (Nantes/FR), M. Lichtenberg (Arnberg/DE), G. Tepe (Rosenheim/DE) |
|
|
|
|
|
|
|
|
13:00-14:00, Room 3.A |
|
|
PharmaCept GmbH |
|
SY 402 |
Updates 2018: DSM-TACE in lung-Ca, ICC and HCC |
|
|
|
|
|
Moderators: R. Iezzi (Rome/IT), T.J. Vogl (Frankfurt/DE) |
|
|
|
402.1
|
原发和继发肺肿瘤的栓塞和局部灌注的现状和未来
Regional chemoperfusion and -embolisation of primary and secondary lung tumours: present and future |
|
|
T.J. Vogl (Frankfurt/DE) |
|
402.2 |
TPCE with DSM: systematic analysis of local and systemic effects in a porcine model |
|
|
P. Isfort (Aachen/DE) |
402.3
|
First survival data for patients with recurrent ICC treated with DSM-TACE after liver resection |
|
|
P. Bruners (Aachen/DE) |
|
402.4 |
DSM-TACE for locally advanced HCC – experiences of Berlin and Rome |
|
|
A. Gross (Berlin/DE), R. Iezzi (Rome/IT) |
|
|
|
|
|
Q & A |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 2 |
|
|
Philips |
|
SY 403 |
Emerging clinical applications in interventional radiology |
|
|
介入放射学最新的临床应用 |
|
|
Moderators: H. Kobeiter (Créteil/FR), J.M. Pisco (Lisbon/PT) |
|
|
|
|
403.1 |
灌注血管造影：再血管化新结果参数
Perfusion angiography: a new outcome parameter for revasularisation |
|
|
J.A. Reekers (Amsterdam/NL) |
|
403.2 |
前列腺动脉栓塞高级3D影像
Advanced 3D imaging in prostatic artery embolisation |
|
|
T. Bilhim (Lisbon/PT) |
|
403.3 |
TACE自动滋养动脉发现的角色
The role of automatic feeder detection in TACE |
|
|
H. Kobeiter (Créteil/FR) |
|
|
|
|
|
|
|
|
16:15-16:35, Room 3.A |
|
|
Qmedics AG |
SY 609
|
Should we ignore the moveability of our arteries? Towards the development of a novel movement-specific stent portfolio |
|
|
|
609.1
|
Should we ignore the moveability of our arteries? Towards the development of a novel movement-specific stent portfolio |
|
|
M. Ferraro (Flurlingen/CH) |
|
|
|
|
|
|
|
Sunday, September 23, 2018 TOP |
|
|
|
|
|
08:00-08:20, Auditorium 2 |
|
|
Endologix International B.V. |
|
SY 802 |
Durability with Ovation: results from the ENCORE analysis |
|
|
|
|
|
Moderator: L. Maene (Aalst/BE) |
|
|
|
|
802.1 |
An introduction to ENCORE: a contemporary analysis of 1296 patients |
|
|
A. Holden (Auckland/NZ) |
|
802.2 |
Clinical experience and lessons learned with Ovation |
|
|
P. Szopinski (Warsaw/PL) |
|
|
|
|
|
|
|
|
08:00-08:20, Raum 3.A |
|
|
Straub Medical AG |
SY 803
|
Safe and effective treatment of occluded veins with purely mechanical thrombectomy |
|
|
|
|
|
Moderators: M. Lichtenberg (Arnsberg/DE), R. Loffroy (Dijon/FR) |
|
|
|
803.1
|
单/多中心髂骨深静脉血栓机械血栓切除的治疗数据
Single and multicentre data on treatment of iliofemoral DVT with mechanical thrombectomy |
|
|
M. Lichtenberg (Arnsberg/DE) |
803.2
|
髂骨静脉深静脉血栓形成治疗策略的概览：不同血凝块切除装置的正反两面
Overview of treatment strategies for iliofemoral DVT. The different clot removal devices-pros and cons |
|
|
T. Heller (Rostock/DE) |
|
|
|
|
|
|
|
|
11:30-12:30, Auditorium 1 |
|
|
Boston Scientific |
SY 1102
|
The growing evidence base on drug eluting technologies: a new focus on drug eluting stent |
|
|
|
|
|
Moderator: M.J. Lee (Dublin/IE) |
|
|
|
|
1102.1 |
The breaking results of the IMPERIAL randomised control trial of Eluvia vs Zilver PTX |
|
|
S. Müller-Hülsbeck (Flensburg/DE) |
|
1102.2 |
周围动脉疾病药物释放的洞悉
Insights into drug delivery in preripheral arterial disease |
|
|
Y. Gouëffic (Nantes/FR) |
|
1102.3 |
Taking Eluvia to below the knee. The SAVAL trial design |
|
|
H. van Overhagen (The Hague/NL) |
|
1102.4 |
Taking Eluvia into critical limb ischaemia. The Munenster experience |
|
|
T. Bisdas (Münster/DE) |
|
1102.5 |
基于周围动脉疾病干预策略的证据
Evidence based algorithm for peripheral arterial disease interventions |
|
|
K.N. Katsanos (Patras/GR) |
|
|
|
|
|
|
|
|
11:30-12:30, Auditorium 8 |
|
|
Sirtex |
SY 1103
|
SIR-Spheres Y-90 resin microspheres continuously improving outcomes for patients |
|
|
|
|
|
Moderators: T.K. Helmberger (Munich/DE), R. Sharma (London/UK) |
|
|
|
|
|
Welcome and introduction |
|
|
|
|
1103.1 |
结直肠癌肝转移：Y90微粒 vs TACE的安全性和证据
mCRC: evidence and safety for SIR-Spheres Y-90 resin microspheres versus TACE |
|
|
H. Mehrzad (Birmingham/UK) |
|
1103.2 |
HCC: upregulation of the immune response with SIR-Spheres Y-90 microspheres |
|
|
B. Sangro (Pamplona/ES) |
1103.3
|
HCC: new insights for better patient selection and treatment strategies with SIR-Spheres Y-90 resin microspheres |
|
|
M. Ronot (Clichy/FR) |
|
1103.4 |
mNETs: further clinical data for SIR-Spheres Y-90 reesin microspheres |
|
|
A.J.A.T. Braat (Utrecht/NL) |
|
1103.5 |
Guidelines: position of SIR-Spheres Y-90 resin microspheres |
|
|
T.K. Helmberger (Munich/DE) |
|
|
|
|
|
Panel discussion |
|
|
|
|
|
|
|
|
11:30-12:30, Auditorium 6 |
|
|
BTG |
SY 1104
|
EKOS acoustic pulse thrombolysis: setting the standard in thrombosis therapy |
|
|
|
|
|
Moderator: K.M. Sterling (Alexandria, VA/US) |
|
|
|
1104.1
|
Over 200 arterial thrombolysis cases with EKOS – sharing experience from the Netherlands |
|
|
R. Lely (Amsterdam/NL) |
|
1104.2 |
EKOS acoustic pulse treatment for acute and chronic DVT |
|
|
M. Dumantepe (Istanbul/TR) |
1104.3
|
OPTALYSE long-term data: multiple protocols – one safe & effective treatment for pulmonary embolism |
|
|
K.M. Sterling (Alexandria, VA/US) |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 6 |
|
|
Guerbet |
|
SY 1201 |
Perfecting your embolisation technique |
|
|
|
|
|
Moderator: G. Maleux (Leuven/BE) |
|
|
|
|
1201.1 |
When and how to use Lipiodol with glue |
|
|
R. Loffroy (Dijon/FR) |
|
1201.2 |
Rebirth of lymphangiography |
|
|
M. Itkin (Philadelphia, PA/US) |
|
1201.3 |
Prevent non-target embolisation for preserving healthy tissue |
|
|
M. Tal (Tel Aviv/IL) |
|
|
|
|
|
Conclusion and Q&A |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 1 |
|
|
Terumo Europe |
|
SY 1202 |
FemPop treatment options from access to closure |
|
|
|
|
|
Theme: Looking at different concepts to master the challenges in femoropopliteal lesion treatment, considering the procedure from the initial puncture through the intervention to the final vessel closure - where are we in 2018? |
|
|
|
|
|
Moderator: S. Müller-Hülsbeck (Flensburg/DE) |
|
|
|
|
1202.1 |
Introduction |
|
|
S. Müller-Hülsbeck (Flensburg/DE) |
|
1202.2 |
Leave nothing behind - the new generation DCB is ready |
|
|
M. Lichtenberg (Arnsberg/DE) |
|
1202.3 |
Traditional Nitinol stents are there to stay |
|
|
Y. Gouëffic (Nantes/FR) |
|
1202.4 |
Double layer stents - innovation that pushes the limit |
|
|
K. Deloose (Dondermonde/BE) |
|
1202.5 |
From access to closure |
|
|
M.G. Manzi (Abano Terme/IT) |
|
1202.6 |
Conclusion |
|
|
S. Müller-Hülsbeck (Flensburg/DE) |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 8 |
|
|
Medtronic Ltd |
|
SY 1203 |
Evidence based approach to liver, lung and kidney microwave ablation |
|
|
|
|
|
Moderator: G. Carrafiello (Milan/IT) |
|
|
|
|
1203.1 |
Evidence review of Emprint microwave ablation |
|
|
P.L. Pereira (Heilbronn/DE) |
|
1203.2 |
The role of the IR |
|
|
F. Orsi (Milan/IT) |
|
1203.3 |
Case based discussion |
|
|
R. Sharma (London/UK) |
|
1203.4 |
Case based discussion |
|
|
D. Ribero (Turin/IT) |
|
|
|
|
|
|
|
|
14:30-15:30, Auditorium 2 |
|
|
Straub Medical AG |
SY 1303
|
Rotarex®S – The 'swiss army knife' for treatment of complex arterial occlusions |
|
|
|
|
|
Moderator: M. Bulvas (Prague/CZ) |
|
|
|
1303.1
|
Mechanical debulking in peripheral interventions: a multitask and effective tool in a widening scenario. Current evidence and technical tips |
|
|
B.L. de Freitas (Leipzig/DE) |
|
1303.2 |
Importance of mechanical debulking in popliteal artery chronic occlusions |
|
|
M. Bulvas (Prague/CZ) |
|
1303.3 |
Debulking instead of stenting in chronic arterial occlusions |
|
|
M. Takes (Basel/CH) |
|
1303.4 |
Vessel preparation before DEB – the Leipzig experience with Rotarex®S |
|
|
S. Braunlich (Halle/DE) |
|
1303.5 |
Clinical and cost effectiveness of Rotarex®S in bypass occlusions |
|
|
B. Migliara (Peschiera del Garda/IT) |
1303.6
|
Endovascular techniques in acute mesenteric ischaemia: novel approaches for a challenging scenario |
|
|
B.L. de Freitas (Leipzig/DE) |
|
|
|
|
|
|
|
|
15:40-16:00, Room 1.15 |
|
|
Alvimedica |
|
SY 1304 |
NiTiDES: an innovative approach for the treatment of SFA lesions |
|
|
|
|
|
Moderator: D. Scheinert (Leipzig/DE) |
|
|
|
|
1304.1 |
Introduction |
|
|
A. Kahlberg (Milano/IT) |
|
1304.2 |
Innovating SFA lesions treatment with NiTiDES |
|
|
R. Langhoff (Berlin/DE) |
|
1304.3 |
ILLUMINA study clinical results |
|
|
D. Scheinert (Leipzig/DE) |
|
1304.4 |
Discussion |
|
1304.5 |
Conclusion |
|
|
A. Kahlberg (Milano/IT) |
|
|
|
|
|
|
|
|
15:40-16:00, Room 3.B |
|
|
Abbott Vascular International |
|
SY 1305 |
Next generation technology for SFA/POP treatment |
|
|
|
|
|
Moderator: K. Deloose (Dendermonde/BE) |
|
|
|
|
1305.1 |
Present and future of DCB technologies |
|
|
J.C. van den Berg (Lugano/CH) |
|
1305.2 |
TRANSCEND DCB study overview |
|
|
M. Brodmann (Graz/AT) |
|
1305.3 |
Going a step ahead with Supera usage |
|
|
K. Deloose (Dendermonde/BE) |
|
|
|
|
|
|
|
|
16:15-16:35, Room 5.B |
|
|
B. Braun Melsungen AG |
|
SY 1410 |
CONSEQUENT less metal – spot stenting & DCB in fempop lesions |
|
|
|
|
|
Moderator: G. Tepe (Rosenheim/DE) |
|
|
|
1410.1
|
Reduce metallic footprints: advantages of short stents vs. long stents in fempop treatment |
|
|
R. Langhoff (Berlin/DE) |
|
1410.2 |
Less is more: indications, treatment and evidence of VascuFlex Multi-LOC |
|
|
K. Deloose (Dendermonde/BE) |
|
1410.3 |
It's the combination that matters: fempop cases with DCB & spot stents |
|
|
M.G. Manzi (Abano Terme/IT) |
|
|
|
|
|
|
|
Monday, September 24, 2018 TOP |
|
|
|
|
|
07:40-08:20, Room 3.A |
|
|
Gore & Associates |
SY 1601
|
New evidence using cTIPS with controlled expansion to treat portal hypertension |
|
|
|
|
|
Moderator: F. Fanelli (Florence/IT) |
|
|
|
1601.1
|
Reviewing new guidelines for the treatment of portal hypertension complications. What has changed? |
|
|
R. Loffroy (Dijon/FR) |
1601.2
|
Initial experience using the GORE® VIATORR® with controlled expansion and the GORE TIPS set |
|
|
R. Miraglia (Palermo/IT) |
1601.3
|
1-year results of a case control study using cTIPS with controlled expansion in patients presented with ascites |
|
|
J. Trebicka (Bonn/DE) |
|
|
|
|
|
|
|
|
11:30-12:30, Auditorium 8 |
|
|
Canon Medical Systems |
|
SY 1902 |
The role of cross-modality imaging in oncology diagnostics and treatment |
|
|
|
|
|
Moderator: A. Denys (Lausanne/CH) |
|
|
|
|
1902.1 |
Improving clinical pathways with Angio CT in abdominal IR |
|
|
B. Guiu (Montpellier/FR) |
|
1902.2 |
Interventional oncology in a state-of-the-art Angio CT environment |
|
|
A. Gangi (Strasbourg/FR) |
|
|
|
|
|
|
|
|
11:30-12:30, Auditorium 1 |
|
|
BD |
|
SY 1903 |
Stenosis in AV access. Evidence-based solutions |
|
|
|
|
|
Moderator: P.M. Kitrou (Patras/GR) |
|
|
|
|
1903.1 |
Update on stenosis in AV access |
|
|
P. Ponce (Lisbon/PT) |
|
1903.2 |
LUTONIX® DCB in AV access. Evidence. Global registry |
|
|
T.M. Steinke (Duesseldorf/DE) |
|
1903.3 |
COVERA® vascular covered stent: latest data and interesting cases |
|
|
B. Dolmach (Mountain View, CA/US) |
|
1903.4 |
AV treatment – an algorithmic approach |
|
|
P.M. Kitrou (Patras/GR) |
|
1903.5 |
Endovascular fistula creation with the WavelinQ EndoAVF System |
|
|
R. Shahverdyan (Hamburg/DE) |
|
|
|
|
|
|
|
|
11:30-12:30, Auditorium 6 |
|
|
Penumbra |
|
SY 1904 |
Penumbra’s latest solutions for embolisation, vessel occlusion, and thrombectomy |
|
|
|
|
|
Moderator: J.F. Benenati (Miami, FL/US) |
|
|
|
1904.1
|
The importance of packing density: how Ruby Coil helps to improve long term recanalisation rates |
|
|
M. Gonsalves (London/UK) |
|
1904.2 |
Dense occlusion with a purposefully designed Packing Coil |
|
|
F. Wolf (Vienna/AT) |
|
1904.3 |
Power aspiration with Indigo System - evolution and clinical data |
|
|
J.F. Benenati (Miami, FL/US) |
1904.4
|
How the Indigo System has changed my practice: thrombus removal in the
periphery |
|
|
F. Elmasri (Lakeland, FL/US) |
|
1904.5 |
Declotting hemodialysis vascular access: early experience with Indigo CATD |
|
|
L.P. Moramarco (Pavia/IT) |
|
|
|
|
|
Debate and discussion |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 6 |
|
|
Guerbet |
|
SY 2001 |
From fundamentals to new frontiers in HCC management |
|
|
|
|
|
Moderator: P.L. Pereira (Heilbronn/DE) |
|
|
|
|
2001.1 |
Updated clinical data on cTACE |
|
|
R. Lencioni (Pisa/IT) |
|
2001.2 |
A new medical device towards cTACE standardisation |
|
|
T. de Baère (Villejuif/FR) |
|
2001.3 |
How to use Lipiodol® to guide local treatments and biopsies? |
|
|
T.J. Vogl (Frankfurt/DE) |
|
|
|
|
|
Conclusion and Q&A |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 1 |
|
|
Cook Medical |
|
SY 2002 |
Treating PAD in the SFA: 'Challenge the status quo' |
|
|
|
|
|
Moderator: M.D. Dake (Stanford, CA/US) |
|
|
|
|
2002.1 |
Introduction |
|
|
M.D. Dake (Stanford, CA/US) |
|
2002.2 |
Exploring the future of DES: XPEDITE |
|
|
E. Blessing (Karlsbad/DE) |
|
2002.3 |
Zilver PTX vs. bypass: first look at 6-month results: ZILVERPASS |
|
|
M. Bosiers (Hamme/BE) |
|
2002.4 |
Zilver PTX pairs well with any balloon |
|
|
K. Deloose (Dendermonde/BE) |
|
2002.5 |
Follow the data: your 2018 treatment algorithm |
|
|
M.D. Dake (Stanford, CA/US) |
|
2002.6 |
Summary, discussion and debate |
|
|
M.D. Dake (Stanford, CA/US) |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 8 |
|
|
Terumo Europe |
|
SY 2003 |
Pushing boundaries in loco regional treatments of liver cancer |
|
|
|
|
|
Theme: Leverage clinical and patient outcome improvements by evolving DEM-TACE and SIRT procedures with innovative devices and techniques. |
|
|
|
|
|
Moderators: B. Guiu (Montpellier/FR), R. Iezzi (Rome/IT) |
|
|
|
|
2003.1 |
Introduction and objectives |
|
|
R. Iezzi (Rome/IT) |
|
|
|
|
|
Building a bright future for DEM-TACE |
|
2003.2 |
New perspectives in DEM-TACE |
|
|
M. Bezzi (Rome/IT) |
|
2003.3 |
Optimising DEM-TACE - case presentation |
|
|
F. Veloso Gomes (Lisbon/PT) |
|
2003.4 |
Discussion |
|
|
|
|
|
From evolution to revolution in SIRT |
|
2003.5 |
Imagine SIRT with dosimetric quantification |
|
|
M.G.E.H. Lam (Utrecht/NL) |
|
2003.6 |
New SIRT opportunitites - case presentation |
|
|
I. Bargellini (Pisa/IT) |
|
2003.7 |
Discussion |
|
|
|
|
2003.8 |
Take home mesages |
|
|
B. Guiu (Montpellier/FR) |
|
|
|
|
|
|
|
|
14:30-15:30, Auditorium 8 |
|
|
Medtronic |
SY 2104
|
Strategies and innovative solutions for success in complex peripheral vascular disease |
|
|
|
|
|
Moderators: F. Fanelli (Florence/IT), K.N. Katsanos (Patras/GR) |
|
|
|
|
2104.1 |
Introduction |
|
|
F. Fanelli (Florence/IT) |
|
2104.2 |
What are the DCB data from real world global trials telling us? |
|
|
G. Goyault (Strasbourg/FR) |
|
2104.3 |
Calcium: the achilles heel of endovascular treatments |
|
|
C. Nolte-Ernsting (Mühlheim/DE) |
|
2104.4 |
What are the consequences of dissections and how can we avoid them? |
|
|
J.C. van den Berg (Lugano/CH) |
|
2104.5 |
Closing remarks |
|
|
K.N. Katsanos (Patras/GR) |
|
|
|
|
|
|
|
|
14:30-15:30, Room 3.A |
|
|
Cardionovum |
SY 2105
|
Can nanocrystalline PTX particles improve DCB treatment outcomes, confidence and reduce procedural stress? |
|
|
|
|
|
Moderators: M. Bosiers (Hamme/BE), M. Lichtenberg (Arnsberg/DE) |
|
|
|
|
2105.1 |
Introduction and learning objectives |
|
|
|
2105.2
|
The LEGDEB registry: 2-year experience with Legflow in de novo and restenotic SFA patients |
|
|
P. Goverde (Antwerp/BE) |
2105.3
|
Long femoropopliteal lesions – results from the ultrasound core lab of the Reflow
trial |
|
|
K. Deloose (Dendermonde/BE) |
2105.4
|
Selecting the most suitable treatment option for CLI patients: the role of atherectomy and SAFEPAX |
|
|
P.H. Haarbrink (Nijmegen/NL) |
2105.5
|
Identifying drivers of long-term success in AV fistula? Lessons learned from the Aperto DCB registry |
|
|
M. Tozzi (Varese/IT) |
|
|
|
|
2105.6 |
Conclusions and closing remarks |
|
|
|
|
|
|
|
|
16:15-16:35, Room 5.A |
|
|
AR Baltic Medical |
|
SY 2209 |
Drug eluting balloon new frontiers |
|
|
|
|
|
Moderator: A. Ruebben (Vilnius/LT) |
|
|
|
2209.1
|
Elutax 3rd generation DCB – short and midterm results on treating ATK and BTK lesions with DCBs |
|
|
F. Strozzi (Reggio Emilia/IT) |
|
2209.2 |
Usage of DCB in non-vascular lesions – initial results and future perspectives |
|
|
I. Lázár (Miskolc/HU) |
|
2209.3 |
Discussion |
|
|
|
|
|
|
|
|
16:15-16:35, Room 3.B |
|
|
Balt |
SY 2210
|
Squidperi liquid embolic agent solution: current use and beyond the boundaries |
|
|
|
|
|
Moderator: H. Kobeiter (Créteil/FR) |
|
|
|
2210.1
|
How Squidperi liquid embolic agent could be considered to treat established indications |
|
|
M. Venturini (Milan/IT) |
|
2210.2 |
High-end embolisation of arterio-venous malformations with Squidperi |
|
|
W.A. Wohlgemuth (Halle/DE) |
|
|
|
|
|
|
|
Tuesday, September 25, 2018 TOP |
|
|
|
|
|
13:00-13:30, Auditorium 2 |
|
|
Bentley |
|
SY 2801 |
Why we do what we do |
|
|
|
|
|
Moderator: R.G. McWilliams (Liverpool/UK) |
|
|
|
|
2801.1 |
The usage of BX covered stents as a bridging stent in complex aortic aneurysms |
|
|
E. Verhoeven (Nuremberg/DE) |
|
2801.2 |
Covered stens as a lifesaver in renal/visceral and iliac injuries |
|
|
M.A. Ruffino (Turin/IT) |
|
2801.3 |
CERAB: the tailor made solution for Aortoiliac Occlusive Disease (AOID) |
|
|
P. Goverde (Antwerp/BE) |
|
|
|
|
|
|
|
|
13:00-14:00, Auditorium 6 |
|
|
Siemens Healthineers |
|
SY 2802 |
Expanding precision medicine in interventional radiology |
|
|
|
|
|
Moderators: W.E.A. Saad (Ann Arbor, MI/US), M.R. Sapoval (Paris/FR) |
|
|
|
|
2802.1 |
Evaluating treatment endpoints in interventional oncology with Angio-CT systems |
|
|
B.C. Odisio (Houston, TX/US) |
2802.2
|
Nexaris Angio-CT: expanding precision medicine in the percutaneous treatment of pelvic metastases |
|
|
S.M. Tutton (Milwaukee, WI/US) |
|
2802.3 |
Image guidance in PAE - reducing radiation dose and improving patient experience |
|
|
C.R. Habermann (Hamburg/DE) |
|
|
|
|
|
|
|
|
13:30-14:00, Auditorium 2 |
|
|
Getinge |
SY 2803
|
Long term results in the treatment of complex aortic diseases - the importance of trusted, reliable, proven, covered stents |
|
|
|
|
|
Moderator: A. Winterbottom (Cambridge/UK) |
|
|
|
|
2803.1 |
Long term results of bridging stent-grafts in FEVAR/BEVAR |
|
|
E. Verhoeven (Nuremberg/DE) |
|
2803.2 |
Bridging stents in fenestrated arch repair |
|
|
T. Kölbel (Hamburg/DE) |
